Innopran Xl is a drug owned by Ani Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 04, 2021. Details of Innopran Xl's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6500454 | Timed, sustained release systems for propranolol |
Oct, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Innopran Xl's patents.
Latest Legal Activities on Innopran Xl's Patents
Given below is the list of recent legal activities going on the following patents of Innopran Xl.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) Critical | 03 Aug, 2010 | US6500454 |
| Correspondence Address Change Critical | 03 Aug, 2010 | US6500454 |
| Post Issue Communication - Certificate of Correction | 27 Mar, 2003 | US6500454 |
| Recordation of Patent Grant Mailed Critical | 31 Dec, 2002 | US6500454 |
| Patent Issue Date Used in PTA Calculation Critical | 31 Dec, 2002 | US6500454 |
| Issue Notification Mailed Critical | 12 Dec, 2002 | US6500454 |
| Receipt into Pubs | 20 Nov, 2002 | US6500454 |
| Application Is Considered Ready for Issue Critical | 18 Nov, 2002 | US6500454 |
| Receipt into Pubs | 07 Nov, 2002 | US6500454 |
| Issue Fee Payment Received Critical | 21 Oct, 2002 | US6500454 |
US patents provide insights into the exclusivity only within the United States, but Innopran Xl is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Innopran Xl's family patents as well as insights into ongoing legal events on those patents.
Innopran Xl's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Innopran Xl's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 04, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Innopran Xl Generic API suppliers:
Propranolol Hydrochloride is the generic name for the brand Innopran Xl. 43 different companies have already filed for the generic of Innopran Xl, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Innopran Xl's generic
Alternative Brands for Innopran Xl
Innopran Xl which is used for treating moderate to severe pain., has several other brand drugs using the same active ingredient (Propranolol Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Pierre Fabre |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Propranolol Hydrochloride, Innopran Xl's active ingredient. Check the complete list of approved generic manufacturers for Innopran Xl
About Innopran Xl
Innopran Xl is a drug owned by Ani Pharmaceuticals Inc. It is used for treating moderate to severe pain. Innopran Xl uses Propranolol Hydrochloride as an active ingredient. Innopran Xl was launched by Ani Pharms in 2003.
Approval Date:
Innopran Xl was approved by FDA for market use on 12 March, 2003.
Active Ingredient:
Innopran Xl uses Propranolol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Propranolol Hydrochloride ingredient
Treatment:
Innopran Xl is used for treating moderate to severe pain.
Dosage:
Innopran Xl is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 120MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 80MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |